Skip to content
The Policy VaultThe Policy Vault

adalimumab (preferred products)Highmark

Psoriatic Arthritis (PsA) without spinal or axial disease

Initial criteria

  • age ≥ 18 years
  • diagnosis of PsA without spinal disease
  • prescribed by or in consultation with a rheumatologist or dermatologist
  • experienced therapeutic failure or intolerance to at least one non-biologic DMARD (for example, methotrexate, leflunomide, sulfasalazine, cyclosporine) OR all non-biologic DMARDs are contraindicated

Reauthorization criteria

  • member has demonstrated disease stability or a beneficial response to therapy